Matinas Biopharma Holdings, Inc.

Common Stock SEC Reporting - Current
Contact Info
  • 1545 Route 206 South
  • Suite 302
  • Bedminster, NJ 07921

Business Description

Update Company Profile
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001582554
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2013
Employees 10 a/o Mar 23, 2016
Company Officers/Contacts
Roelof Rongen CEO
Jerry Jabbour President, General Counsel, EVP
Gary Gaglione Interim CFO
Abdel Fawzy EVP, Bus. Affairs
Douglas F. Kling Senior VP
Raphael J. Mannino CSO, CTO
Company Directors
Herbert Conrad Chairman
Stefano Ferrari
Roelof Rongen
James Scibetta
Adam Stern
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP
111 Wood Avenue South
Suite 600
Iselin, NJ, 08830-2700
United States
Securities Counsel
Lowenstein Sandler LLP (NJ)
65 Livingston Avenue
Roseland, NJ, 07068
United States
Investor Relations Firm
Jenene Thomas Communications, LLC
48 Sky Manor Road, G4
Pittstown, NJ, 08867
United States
MTNB Security Details
Share Structure
Market Value1 $190,239,014 a/o Feb 17, 2017
Authorized Shares 250,000,000 a/o Jan 30, 2017
Outstanding Shares 58,715,745 a/o Jan 30, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 31,187,778 a/o Jan 20, 2017
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders of Record 340 a/o Jan 20, 2017
Short Selling Data
Short Interest 265,482 (44.06%)
Jan 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security